Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 83
Filtrar
1.
Gastroenterol Hepatol ; 47(2): 119-129, 2024 Feb.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-36870477

RESUMO

INTRODUCTION AND AIMS: The outcomes of endoscopic submucosal dissection (ESD) in the esophagus have not been assessed in our country. Our primary aim was to analyze the effectiveness and safety of the technique. MATERIAL AND METHODS: Analysis of the prospectively maintained national registry of ESD. We included all superficial esophageal lesions removed by ESD in 17 hospitals (20 endoscopists) between January 2016 and December 2021. Subepithelial lesions were excluded. The primary outcome was curative resection. We conducted a survival analysis and used logistic regression analysis to assess predictors of non-curative resection. RESULTS: A total of 102 ESD were performed on 96 patients. The technical success rate was 100% and the percentage of en-bloc resection was 98%. The percentage of R0 and curative resection was 77.5% (n=79; 95%CI: 68%-84%) and 63.7% (n=65; 95%CI: 54%-72%), respectively. The most frequent histology was Barrett-related neoplasia (n=55 [53.9%]). The main reason for non-curative resection was deep submucosal invasion (n=25). The centers with a lower volume of ESD obtained worse results in terms of curative resection. The rate of perforation, delayed bleeding and post-procedural stenosis were 5%, 5% and 15.7%, respectively. No patient died or required surgery due to an adverse effect. After a median follow-up of 14months, 20patients (20.8%) underwent surgery and/or chemoradiotherapy, and 9 patients died (mortality 9.4%). CONCLUSIONS: In Spain, esophageal ESD is curative in approximately two out of three patients, with an acceptable risk of adverse events.


Assuntos
Ressecção Endoscópica de Mucosa , Neoplasias Esofágicas , Humanos , Neoplasias Esofágicas/cirurgia , Neoplasias Esofágicas/patologia , Ressecção Endoscópica de Mucosa/efeitos adversos , Ressecção Endoscópica de Mucosa/métodos , Espanha , Resultado do Tratamento , Estudos Retrospectivos
2.
Cir Esp (Engl Ed) ; 101 Suppl 4: S39-S42, 2023 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-37979936

RESUMO

Sleeve gastrectomy has become the most performed bariatric surgery technique in the world. This bariatric technique has been related to the appearance of gastroesophageal reflux and recently with de novo Barrett's esophagus. It is not clear that this leads to an increased incidence of esophageal adenocarcinoma. In this review we analyze the current scientific literature to try to answer the true incidence of Barrett's esophagus and adenocarcinoma after sleeve gastrectomy, and whether these data should make us change the indications for this technique.


Assuntos
Adenocarcinoma , Esôfago de Barrett , Neoplasias Esofágicas , Refluxo Gastroesofágico , Humanos , Esôfago de Barrett/epidemiologia , Esôfago de Barrett/etiologia , Esôfago de Barrett/patologia , Neoplasias Esofágicas/epidemiologia , Neoplasias Esofágicas/cirurgia , Neoplasias Esofágicas/etiologia , Adenocarcinoma/epidemiologia , Adenocarcinoma/cirurgia , Adenocarcinoma/etiologia , Refluxo Gastroesofágico/etiologia , Refluxo Gastroesofágico/complicações , Gastrectomia/efeitos adversos , Gastrectomia/métodos
3.
Rev Med Inst Mex Seguro Soc ; 61(Suppl 2): S233-S238, 2023 Sep 18.
Artigo em Espanhol | MEDLINE | ID: mdl-38016098

RESUMO

Background: Barrett's esophagus (BE) is the replacement of the usual esophageal mucosa by a simple columnar epithelium with the presence of goblet cells (GC) of intestinal type. It has been related to different risk factors such as gastroesophageal reflux disease (GERD), inappropriate consumption of irritating foods, smoking and overweight. There are CC mimic cells, known as blue cells (BC), which make the diagnosis of BE difficult, due to the lack of a precise definition of the nature and location of the gastroesophageal junction and the microscopic variations in this area. Objective: To identify morphologically and with histochemical techniques Alcian blue (AA) and periodic acid-Schiff (PAS) between GC and BC. Material and methods: Retrolective cross-sectional analytical study where 45 samples of patients diagnosed with BE were included. Results: The morphological characteristics are similar in both cell varieties. PAS staining was 100%, unlike AA staining, with only 16 cases with staining, corresponding to 35.55%. Conclusions: PAS staining has a high sensitivity and specificity for the identification of GC, this being a fundamental pillar for the correct diagnosis of BE. The presence of BC detected by AA does not exclude the diagnosis of BE, since both cell types can coexist.


Introducción: el esófago de Barrett (EB) es el recambio de la mucosa habitual esofágica por un epitelio cilíndrico simple con presencia de células caliciformes (CC) de tipo intestinal. Se ha relacionado con factores de riesgo como la enfermedad por reflujo gastroesofágico (ERGE), consumo inapropiado de alimentos irritantes, tabaquismo o sobrepeso. Hay células imitadoras de las CC, las células azules (CA), que dificultan el diagnóstico del EB y es debido a falta de una definición precisa sobre la naturaleza y ubicación de la unión gastroesofágica y las variaciones microscópicas en esta zona. Objetivo: identificar morfológicamente y con las técnicas de histoquímica azul alciano (AA) y ácido peryódico de Schiff (PAS) las CC y las CA. Material y métodos: estudio transversal retrolectivo analítico; se incluyeron 45 muestras de pacientes diagnosticados con EB. Resultados: las características morfológicas son similares en ambas variedades celulares. La tinción de PAS fue del 100%, a diferencia de la tinción de AA, con solo 16 casos con tinción, correspondiente al 35.55%. Conclusiones: la tinción de PAS tiene una alta sensibilidad y especificidad para la identificación de CC, lo cual es fundamental para el correcto diagnóstico de la EB. La presencia de CA detectadas mediante AA no excluye el diagnóstico de EB, ya que ambos tipos celulares pueden coexistir.


Assuntos
Esôfago de Barrett , Humanos , Esôfago de Barrett/diagnóstico , Esôfago de Barrett/complicações , Esôfago de Barrett/metabolismo , Células Caliciformes/metabolismo , Estudos Transversais , Azul Alciano/metabolismo
4.
Gastroenterol. hepatol. (Ed. impr.) ; 46(8): 637-644, oct. 2023. tab, ilus
Artigo em Inglês | IBECS | ID: ibc-225946

RESUMO

Although low-grade dysplasia (LGD) in Barrett's esophagus (BE) is a histopathological diagnosis based on different histological abnormalities, it is still problematic for different reasons. Patients without confirmed diagnosis of LGD undergo unnecessary and intensified follow-up where the risk of progression is low in the majority of cases. In contrast, the presence of confirmed LGD indicates a high risk of progression. In this article we try to address these reasons focusing on re-confirmation of LGD diagnosis, interobserver agreement, and persistent confirmed LGD. The progression risk of LGD to high-grade dysplasia and esophageal adenocarcinoma will also be reviewed. (AU)


Aunque la displasia de bajo grado (DBG) en el esófago de Barrett (EB) es un diagnóstico histopatológico basado en diferentes anomalías histológicas, este no deja de ser problemático por diferentes razones. Los pacientes sin diagnóstico confirmado de DBG se someten a un seguimiento innecesario e intensificado donde el riesgo de progresión es bajo en la mayoría de los casos. Por el contrario, la presencia de DBG confirmada indica un alto riesgo de progresión. En este artículo tratamos de abordar estas razones centrándonos en la reconfirmación del diagnóstico de la DBG, la concordancia entre observadores y la DBG confirmada y persistente. También se revisará el riesgo de progresión de la DBG a displasia de alto grado y adenocarcinoma esofágico. (AU)


Assuntos
Humanos , Esôfago de Barrett , Hiperplasia/complicações , Hiperplasia/diagnóstico , Risco , Adenocarcinoma
5.
Gastroenterol. hepatol. (Ed. impr.) ; 46(5): 360-368, May. 2023. ilus, tab, graf
Artigo em Espanhol | IBECS | ID: ibc-220006

RESUMO

Antecedentes: El esófago de Barrett (EB) es una entidad con una progresión histológica a malignidad conocida. Los factores de crecimiento insulínico (IGF, de insulin-like growth factor) están involucrados en la carcinogénesis asociada a la obesidad y se han asociado con el riesgo de padecer algunos tipos de cáncer. Objetivos: Evaluar los niveles serológicos de IGF-1 e IGFBP-3 en pacientes con EB y adenocarcinoma de esófago. Pacientes y métodos: Estudio prospectivo de pacientes con EB y adenocarcinoma de esófago explorados con gastroscopia entre septiembre 2012 y diciembre 2015 a los que se realizó una extracción de sangre para la determinación de IGF-1 e IGFBP-3. Se incluyó un grupo control. Resultados: Se incluyeron 116 pacientes: 36 controles, 62 con EB (42 sin displasia y 20 con displasia) y 18 con adenocarcinoma. El IGF-1 y la ratio molar IGF-1/IGFBP-3 presentaron un aumento progresivo en los grupos con EB y adenocarcinoma comparado con los controles (IGF-1: 135,55±66,07ng/ml; 148,33±81,5ng/ml; 108,19±46,69ng/ml, respectivamente; p=0,049) (ratio molar: 0,23±0,91; 0,29±0,11; 0,19±0,06, respectivamente; p=0,001), sin diferencias entre los diferentes grados histológicos. Cincuenta y cuatro de los 65 pacientes con EB fueron seguidos durante una mediana de 58,50 meses (12-113) y 11 de ellos (20,4%) presentaron progresión a displasia de bajo grado (n=8) o displasia de alto grado/adenocarcinoma (n=3), sin encontrar diferencias en el sistema IGF comparado con los que no progresaron. Conclusiones: Los pacientes con EB y adenocarcinoma esofágico presentan cambios en el sistema IGF aunque los niveles de IGF-1 e IGFBP-3 no se correlacionan con la progresión histológica del EB.(AU)


Background: Barrett's esophagus (BE) is an entity with a known histological progression to malignancy. The insulin-like growth factor (IGF) system is involved in the carcinogenesis through obesity-related mechanisms that include IGF and it has been associated with several types of cancer. Objectives: To evaluate the serological levels of IGF-1 and IGFBP-3 in patients with BE and esophageal adenocarcinoma. Patients and methods: Prospective study of patients with BE and esophageal adenocarcinoma who underwent upper endoscopy between September 2012 and December 2015. A baseline determination of IGF-1 and IGFBP-3 was performed. We included a control group of patients without BE. Results: One hundred sixteen patients were included: 36 controls, 62 with BE (42 without dysplasia and 20 with dysplasia) and 18 with adenocarcinoma. IGF-1 and IGF-1/IGFBP-3 molar ratio showed a progression to high levels in BE and adenocarcinoma than in controls (IGF-1: 135.55±66.07ng/ml, 148.33±81.5ng/ml, 108.19±46.69ng/ml, respectively; P=.049) (molar ratio: 0.23±0.91, 0.29±0.11, 0.19±0.06, respectively; P=.001), without differences between the histological types of BE. Fifty-four out of the 65 patients with BE were followed up (median of 58.50 months, range 12–113) and 11 of them (20.4%) presented progression to low-grade dysplasia (n=8) or high-grade dysplasia/adenocarcinoma (n=3), without differences in the IGF system compared with patients without progression. Conclusions: Patients with BE and esophageal adenocarcinoma have changes in the IGF system although the serological levels of IGF-1 and IGFBP-3 do not correlate with histological progression of BE.(AU)


Assuntos
Humanos , Esôfago de Barrett , Adenocarcinoma , Esôfago , Proteína 3 de Ligação a Fator de Crescimento Semelhante à Insulina , Fator de Crescimento Insulin-Like I , Estudos Longitudinais , Estudos Prospectivos
6.
Gastroenterol Hepatol ; 46(8): 637-644, 2023 Oct.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-36243250

RESUMO

Although low-grade dysplasia (LGD) in Barrett's esophagus (BE) is a histopathological diagnosis based on different histological abnormalities, it is still problematic for different reasons. Patients without confirmed diagnosis of LGD undergo unnecessary and intensified follow-up where the risk of progression is low in the majority of cases. In contrast, the presence of confirmed LGD indicates a high risk of progression. In this article we try to address these reasons focusing on re-confirmation of LGD diagnosis, interobserver agreement, and persistent confirmed LGD. The progression risk of LGD to high-grade dysplasia and esophageal adenocarcinoma will also be reviewed.


Assuntos
Adenocarcinoma , Esôfago de Barrett , Neoplasias Esofágicas , Lesões Pré-Cancerosas , Humanos , Esôfago de Barrett/complicações , Esôfago de Barrett/diagnóstico , Esôfago de Barrett/patologia , Lesões Pré-Cancerosas/patologia , Progressão da Doença , Neoplasias Esofágicas/diagnóstico , Neoplasias Esofágicas/etiologia , Neoplasias Esofágicas/patologia , Adenocarcinoma/diagnóstico , Adenocarcinoma/etiologia , Adenocarcinoma/patologia , Hiperplasia
7.
Gastroenterol Hepatol ; 46(5): 360-368, 2023 May.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-36179948

RESUMO

BACKGROUND: Barrett's esophagus (BE) is an entity with a known histological progression to malignancy. The insulin-like growth factor (IGF) system is involved in the carcinogenesis through obesity-related mechanisms that include IGF and it has been associated with several types of cancer. OBJECTIVES: To evaluate the serological levels of IGF-1 and IGFBP-3 in patients with BE and esophageal adenocarcinoma. PATIENTS AND METHODS: Prospective study of patients with BE and esophageal adenocarcinoma who underwent upper endoscopy between September 2012 and December 2015. A baseline determination of IGF-1 and IGFBP-3 was performed. We included a control group of patients without BE. RESULTS: One hundred sixteen patients were included: 36 controls, 62 with BE (42 without dysplasia and 20 with dysplasia) and 18 with adenocarcinoma. IGF-1 and IGF-1/IGFBP-3 molar ratio showed a progression to high levels in BE and adenocarcinoma than in controls (IGF-1: 135.55±66.07ng/ml, 148.33±81.5ng/ml, 108.19±46.69ng/ml, respectively; P=.049) (molar ratio: 0.23±0.91, 0.29±0.11, 0.19±0.06, respectively; P=.001), without differences between the histological types of BE. Fifty-four out of the 65 patients with BE were followed up (median of 58.50 months, range 12-113) and 11 of them (20.4%) presented progression to low-grade dysplasia (n=8) or high-grade dysplasia/adenocarcinoma (n=3), without differences in the IGF system compared with patients without progression. CONCLUSIONS: Patients with BE and esophageal adenocarcinoma have changes in the IGF system although the serological levels of IGF-1 and IGFBP-3 do not correlate with histological progression of BE.


Assuntos
Adenocarcinoma , Esôfago de Barrett , Neoplasias Esofágicas , Humanos , Esôfago de Barrett/metabolismo , Esôfago de Barrett/patologia , Estudos Longitudinais , Proteína 3 de Ligação a Fator de Crescimento Semelhante à Insulina , Fator de Crescimento Insulin-Like I/metabolismo , Estudos Prospectivos , Progressão da Doença , Neoplasias Esofágicas/patologia , Adenocarcinoma/patologia
8.
ABCD (São Paulo, Online) ; 36: e1760, 2023. tab, graf
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1513516

RESUMO

ABSTRACT BACKGROUND: The addition of endoscopic ablative therapy plus proton pump inhibitors or fundoplication is postulated for the treatment of patients with long-segment Barrett´s esophagus (LSBE); however, it does not avoid acid and bile reflux in these patients. Fundoplication with distal gastrectomy and Roux-en-Y gastrojejunostomy is proposed as an acid suppression-duodenal diversion procedure demonstrating excellent results at long-term follow-up. There are no reports on therapeutic strategy with this combination. AIMS: To determine the early and long-term results observed in LSBE patients with or without low-grade dysplasia who underwent the acid suppression-duodenal diversion procedure combined with endoscopic therapy. METHODS: Prospective study including patients with endoscopic LSBE using the Prague classification for circumferential and maximal lengths and confirmed by histological study. Patients were submitted to argon plasma coagulation (21) or radiofrequency ablation (31). After receiving treatment, they were monitored at early and late follow-up (5-12 years) with endoscopic and histologic evaluation. RESULTS: Few complications (ulcers or strictures) were observed after the procedure. Re-treatment was required in both groups of patients. The reduction in length of metaplastic epithelium was significantly better after radiofrequency ablation compared to argon plasma coagulation (10.95 vs 21.15 mms for circumferential length; and 30.96 vs 44.41 mms for maximal length). Intestinal metaplasia disappeared in a high percentage of patients, and histological long-term results were quite similar in both groups. CONCLUSIONS: Endoscopic procedures combined with fundoplication plus acid suppression with duodenal diversion technique to eliminate metaplastic epithelium of distal esophagus could be considered a good alternative option for LSBE treatment.


RESUMO RACIONAL: A adição de terapia ablativa endoscópica associado a inibidores da bomba de prótons ou fundoplicatura tem sido postulada para o tratamento de pacientes com esôfago de Barrett de segmento longo (EBSL), no entanto, essa conduta não evita o refluxo ácido/biliar nesses pacientes. A fundoplicatura com gastrectomia distal e gastrojejunostomia em Y de Roux (FGD-Y) foi proposta como procedimento de supressão de ácido, demonstrando excelentes resultados no seguimento a longo prazo. Não há relatos na literature com a combinação dessa estratégia terapêutica. OBJETIVOS: Determinar os resultados precoces e a longo prazo observados em pacientes com EBSL com ou sem dysplasia de baixo grau, submetidos a FGD-Y, combinado com terapia endoscópica. MÉTODOS: Estudo prospectivo incluindo pacientes com EBSL, empregando a classificação de Praga, sendo o comprimento circunferencial (C) e máximo (M) e confirmado por estudo histológico. Os pacientes foram submetidos à coagulação com plasma de argônio (CPA, 21 pacientes) ou ablação por radiofrequência (ARF, 31 pacientes). Após o tratamento, eles foram seguidos precoce e tardiamente (5-12 anos), mediante avaliação endoscópica e histológica. RESULTADOS: Foram observadas poucas complicações após o procedimento (úlcera ou estenose). Re-tratamento foi necessário em ambos os grupos de pacientes. A redução do comprimento do epitélio metaplásico foi significativamente melhor após ARF em comparação com CPA (10,95 versus 21,15 mm para C e 30,96 versus 44,41 mm para M). A metaplasia intestinal desapareceu em elevada porcentagem de pacientes, e os resultados histológicos a longo prazo foram bastante semelhantes em ambos os grupos. CONCLUSÕES: Procedimentos endoscópicos combinados com fundoplicatura e gastrectomia distal e gastrojejunostomia em Y de Roux, para eliminar o epitélio metaplásico do esôfago distal podem ser considerados uma boa opção alternativa para o tratamento da EBSL.

9.
ABCD arq. bras. cir. dig ; 36: e1786, 2023. tab
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1527553

RESUMO

ABSTRACT Despite endoscopic eradication therapy being an effective and durable treatment for Barrett's esophagus-related neoplasia, even after achieving initial successful eradication, these patients remain at risk of recurrence and require ongoing routine examinations. Failure of radiofrequency ablation and argon plasma coagulation is reported in 10-20% of cases.


RESUMO Apesar de a terapia de erradicação endoscópica ser um tratamento eficaz e durável para a neoplasia relacionada ao esôfago de Barrett (BE), mesmo após a erradicação inicial bem-sucedida, esses pacientes permanecem em risco de recorrência e requerem exames de rotina contínuos. A falha na ablação por radiofrequência e na coagulação com plasma de argônio é relatada em 10-20% dos casos.

10.
Rev. gastroenterol. Peru ; 42(4)oct. 2022.
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1423949

RESUMO

Barrett's esophagus (BE) is a known precursor of dysplasia and adenocarcinoma. Endoscopic resection and surgery are the techniques used to treat these kinds of lesions. However, endoscopic resection is considered the first choice for the management of superficial lesions. Dysplasia in BE most commonly appears like a flat lesion but here we describe an unusual case of dysplasia and superficial adenocarcinoma looking like an extensive polypoid lesion.


El esófago de Barrett (EB) es un precursor conocido de displasia y adenocarcinoma. La resección endoscópica y la cirugía son las técnicas utilizadas para tratar este tipo de lesiones. Sin embargo, la resección endoscópica se considera la primera opción para el manejo de las lesiones superficiales. La displasia en EB aparece más comúnmente como una lesión plana, pero aquí describimos un caso inusual de displasia y adenocarcinoma superficial que parece una lesión polipoide extensa.

11.
Medicentro (Villa Clara) ; 26(3): 637-656, jul.-set. 2022. tab, graf
Artigo em Espanhol | LILACS | ID: biblio-1405661

RESUMO

RESUMEN Introducción: El esófago de Barrett es una condición esofágica adquirida, que puede evolucionar a un adenocarcinoma. Con el paso de los años, la terapia endoscópica ha remplazado la cirugía en el tratamiento de esta afección. Objetivos: Mostrar los resultados de la aplicación de la técnica de resección endoscópica de la mucosa y la ablación con Hibrid-APC en pacientes portadores de esófago de Barrett con displasia de bajo o alto grado. Métodos: Se realizó un estudio descriptivo y retrospectivo en 29 pacientes entre los años 2014-2019, en el Servicio de endoscopias del Centro Nacional de Cirugía de Mínimo Acceso. Se estudiaron variables sociodemográficas, se estableció la clasificación endoscópica del esófago de Barrett, se describieron las características de la lesión, el diagnóstico histológico, la terapéutica endoscópica, la presencia de complicaciones, la resección incompleta y recidiva. Se aplicaron técnicas de estadística descriptiva y métodos no paramétricos. Resultados: Predominó el sexo masculino (58,62 %) y el grupo de 41-60 años (58,62 %). El segmento corto con lesiones planas y el largo con lesiones elevadas fueron más frecuentes (37,93 %). Se realizaron 15 resecciones y 14 ablaciones con Hibrid-APC; se observó una estenosis como complicación de la resección endoscópica de la mucosa y recidivas con ambas técnicas (5 pacientes, 17 %), tres relacionadas con la resección y dos con el Hibrid-APC. El Hibrid-APC alcanzó una efectividad terapéutica del 85,71 % y la resección del 80 %. Conclusiones: El tratamiento endoscópico con displasia de bajo y alto grado, mostró ser un procedimiento efectivo y seguro, con bajo porciento de complicaciones y recidivas.


ABSTRACT Introduction: Barrett's esophagus is an acquired esophageal condition that can evolve into an adenocarcinoma. Over the years, endoscopic therapy has replaced surgery in the treatment of this condition. Objectives: to show the results of the application of the endoscopic mucosal resection and Hybrid-APC ablation technique in patients with Barrett's esophagus with low-grade or high-grade dysplasia. Methods: a descriptive and retrospective study was carried out in 29 patients between 2014 and 2019, in the Endoscopy service of the National Center for Minimal Access Surgery. Social and demographic variables were studied; endoscopic classification of Barrett's esophagus was established, as well as the characteristics of the lesion, histological diagnosis, endoscopic therapy, the presence of complications, incomplete resection and recurrence were described. Descriptive statistics techniques and non-parametric methods were applied. Results: male gender (58.62%) and the group aged 41-60 years (58.62%) predominated. The short segment with flat lesions and the long segment with raised lesions were more frequent (37.93%). A number of 15 resections and 14 ablations were performed with Hybrid-APC; one stricture was observed as a complication of endoscopic mucosal resection and recurrences with both techniques (5 patients, 17%), three related to resection and two to Hybrid-APC. The Hybrid-APC achieved a therapeutic effectiveness of 85.71% and the resection one of 80%. Conclusions: endoscopic treatment with low- and high-grade dysplasia proved to be an effective and safe procedure, with a low percentage of complications and recurrences.


Assuntos
Esôfago de Barrett/cirurgia , Cirurgia Endoscópica por Orifício Natural , Coagulação com Plasma de Argônio
12.
Med. clín (Ed. impr.) ; 159(2): 92-100, julio 2022. tab
Artigo em Espanhol | IBECS | ID: ibc-206307

RESUMO

La principal relevancia clínica del esófago de Barrett (EB), resultado de la exposición crónica al reflujo gastroesofágico, es su potencial progresión a adenocarcinoma esofágico (ACE). Aunque no se recomienda el cribado de EB en la población general, tras su diagnóstico es beneficiosa una estrategia de seguimiento para la detección precoz de displasia o neoplasia. El patrón oro para el diagnóstico y seguimiento es la endoscopia oral de alta definición con toma de biopsias aleatorias. Además, toda lesión visible debe resecarse de forma completa preferentemente mediante resección endoscópica mucosa, que se considerará curativa en presencia de displasia de bajo grado (DBG), displasia de alto grado (DAG) o ACE confinado a la mucosa (T1a), tras lo cual se debe erradicar el EB residual mediante ablación endoscópica. En ausencia de lesión visible, la ablación por radiofrecuencia es el tratamiento de elección para erradicar el EB con DBG, DAG o ACE intramucoso. (AU)


The main clinical relevance of Barrett's esophagus (BE), a result of chronic exposure to gastroesophageal reflux, is its potential progression to esophageal adenocarcinoma (EAC). Although screening for BE is not recommended in the general population, after diagnosis of BE, a surveillance strategy for early detection of dysplasia or neoplasia is needed. The gold standard for diagnosis and surveillance is high-definition oral endoscopy with random biopsies. In addition, any visible lesion should be completely resected, which will be considered curative in the presence of low grade dysplasia (LGD), high-grade dysplasia (HGD) or EAC confined to the mucosa (T1a), followed by eradication of residual BE by endoscopic ablation. In the absence of a visible lesion, radiofrequency ablation should be performed to eradicate BE with LGD, HGD or intramucosal EAC. (AU)


Assuntos
Humanos , Adenocarcinoma/diagnóstico , Adenocarcinoma/epidemiologia , Adenocarcinoma/cirurgia , Esôfago de Barrett/diagnóstico , Esôfago de Barrett/epidemiologia , Esôfago de Barrett/terapia , Hiperplasia , Lesões Pré-Cancerosas/diagnóstico , Lesões Pré-Cancerosas/patologia , Lesões Pré-Cancerosas/cirurgia , Biópsia , Esofagoscopia
13.
Med Clin (Barc) ; 159(2): 92-100, 2022 07 22.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-35606193

RESUMO

The main clinical relevance of Barrett's esophagus (BE), a result of chronic exposure to gastroesophageal reflux, is its potential progression to esophageal adenocarcinoma (EAC). Although screening for BE is not recommended in the general population, after diagnosis of BE, a surveillance strategy for early detection of dysplasia or neoplasia is needed. The gold standard for diagnosis and surveillance is high-definition oral endoscopy with random biopsies. In addition, any visible lesion should be completely resected, which will be considered curative in the presence of low grade dysplasia (LGD), high-grade dysplasia (HGD) or EAC confined to the mucosa (T1a), followed by eradication of residual BE by endoscopic ablation. In the absence of a visible lesion, radiofrequency ablation should be performed to eradicate BE with LGD, HGD or intramucosal EAC.


Assuntos
Adenocarcinoma , Esôfago de Barrett , Neoplasias Esofágicas , Lesões Pré-Cancerosas , Adenocarcinoma/diagnóstico , Adenocarcinoma/epidemiologia , Adenocarcinoma/cirurgia , Esôfago de Barrett/diagnóstico , Esôfago de Barrett/epidemiologia , Esôfago de Barrett/terapia , Biópsia , Neoplasias Esofágicas/diagnóstico , Neoplasias Esofágicas/cirurgia , Esofagoscopia , Humanos , Hiperplasia , Lesões Pré-Cancerosas/diagnóstico , Lesões Pré-Cancerosas/patologia , Lesões Pré-Cancerosas/cirurgia
14.
Rev. cuba. med. mil ; 51(1)mar. 2022.
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1408788

RESUMO

RESUMEN Introducción: El esófago de Barrett es una lesión del esófago con elevado potencial degenerativo; para su diagnóstico se requiere la confirmación histológica de metaplasia intestinal en el esófago. Objetivo: Determinar la prevalencia del esófago de Barrett y las características epidemiológicas de los pacientes con esta afección. Métodos: Se realizó un estudio observacional descriptivo, entre enero del 2018 y junio del 2019, en 14 pacientes con diagnóstico histológico de esófago de Barrett. Las variables estudiadas fueron: edad, sexo, color de la piel, antecedentes epidemiológicos, síntomas y signos, longitud del segmento, de acuerdo con la clasificación de Sharma y presencia de hernia hiatal. Se realizó el diagnóstico histológico según la clasificación de Viena. Se determinó la prevalencia respecto del total de endoscopias digestivas altas realizadas en el periodo; emplearon de estadísticas descriptivas. Resultados: Se obtuvo una prevalencia de 0,37 %. El sexo masculino (78,6 %) y el color de piel blanca (71,4 %) predominaron; la edad media fue de 51,64 años. El consumo de tabaco fue referido por el 50 % de los pacientes. Los síntomas típicos de reflujo gastroesofágico, regurgitación (64,3 %) y pirosis (42,9 %) fueron los más frecuentes. La variedad de segmento corto fue la más observada y la hernia hiatal se encontró en 28,6 % de los casos. Conclusiones: Predominan las características epidemiológicas de ser pacientes masculinos, color de piel blanca, entre la 5ta y 6ta décadas de la vida y síntomas típicos de enfermedad por reflujo gastroesofágico. La prevalencia de la afección es baja.


ABSTRACT Introduction: Barrett's esophagus is an injury to the esophagus with high degenerative potential; histological confirmation of intestinal metaplasia in the esophagus is required for its diagnosis. Objective: To determine the frequency and epidemiological characteristics of patients with Barrett's esophagus. Methods: An observational and descriptive study was conducted between January 2018 and June 2019 in 14 patients with a histological diagnosis of Barrett's esophagus. The variables studied were: age, sex, skin color, epidemiological history, symptoms and signs, segment length according to the Sharma classification and presence of hiatal hernia, as well as the histological diagnosis according to the Vienna classification. The prevalence was determined with respect to the total number of upper gastrointestinal endoscopies performed in the period; descriptive statistical techniques were used. Results: A prevalence of 0,37 % was obtained. Males (78,6 %) and white skin color (71,4 %) predominated; the mean age was 51,64 years. Smoking was reported by 50 % of patients. Typical symptoms of gastroesophageal reflux, regurgitation (64,3 %) and heartburn (42,9 %) were the most frequent. The short segment variety was the most observed and hiatal hernia was found in 28,6 % of cases. Conclusions: The epidemiological characteristics of male patients, white skin color, between the 5th and 6th decades of life and typical symptoms of gastroesophageal reflux disease predominate.

16.
ABCD (São Paulo, Online) ; 35: e1674, 2022. tab, graf
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1402860

RESUMO

ABSTRACT BACKGROUND: Barrett's esophagus is an acquired condition that predisposes to the development of esophageal adenocarcinoma. AIMS: The aim of this study was to establish an association between the endoscopic and the histopathological findings regarding differently sized endoscopic columnar epithelial mucosa projections in the low esophagus, under 3.0 cm in the longitudinal extent. METHODS: This is a prospective study, including 1262 patients who were submitted to upper gastrointestinal endoscopy in the period from July 2015 to June 2017. The suspicious projections were measured and subdivided into three groups according to the sizes encountered (Group I: <0.99 cm; Group II: 1.0-1.99 cm; and Group III: 2.0-2.99 cm), and biopsies were then performed. RESULTS: There was a general prevalence of suspicious lesions of 6.42% and of confirmed Barrett's lesions of 1.17%, without a general significant statistical difference among groups. However, from Groups I and II to Group III, the differences were significant, showing that the greater the lesion, the higher the probability of Barrett's esophagus diagnosis. The absolute number of Barrett's lesions was 7, 9, and 6 for Groups I, II, and III, respectively. CONCLUSIONS: The findings led to the conclusion that even projections under 3.0 cm present a similar possibility of evolution to Barrett's esophagus. If, on the one hand, short segments are more prevalent, on the other hand, the long segments have the higher probability of Barrett's esophagus diagnosis, which is why biopsies are required in all suspicious segments.


RESUMO RACIONAL: O esôfago de Barrett é uma condição adquirida que predispõe ao desenvolvimento de adenocarcinoma de esôfago. OBJETIVOS: Estabelecer uma associação entre os achados endoscópicos e histopatológicos em relação às projeções endoscópicas da mucosa epitelial colunar de diferentes tamanhos no esôfago, abaixo de 3,0 centímetros de extensão longitudinal. MÉTODOS: Foi realizado um estudo prospective incluindo 1262 pacientes submetidos à endoscopia digestiva alta, no período de julho de 2015 a junho de 2017. As projeções suspeitas foram medidas, subdivididas em 3 grupos de acordo com os tamanhos encontrados (Grupo I: <0,99 cm; Grupo II: 1,0 cm-1,99 cm; Grupo III: 2,0 cm-2,99 cm) e biópsias foram então realizadas. RESULTADOS: Houve prevalência geral de lesões suspeitas de 6,42% e de lesões de Barrett confirmadas de 1,17%, sem diferença estatística geral significativa entre os grupos. Porém, dos Grupos I e II, para o Grupo III, as diferenças foram significativas, mostrando que quanto maior a lesão, maior a probabilidade de diagnóstico de esôfago de Barrett. O número absoluto de lesões de Barrett foi 7, 9 e 6 para os grupos I, II e III, respectivamente. CONCLUSÕES: Os achados permitiram concluir que mesmo projeções abaixo de 3,0 cm apresentam possibilidade semelhante de evolução para o esôfago de Barrett. Se, por um lado os segmentos curtos são mais prevalentes, por outro os segmentos longos têm maior probabilidade de diagnóstico de esôfago de Barrett, razão pela qual são necessárias biópsias em todos os segmentos suspeitos.

17.
Arq. gastroenterol ; 58(2): 195-201, Apr.-June 2021. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1285325

RESUMO

ABSTRACT BACKGROUND: Endoscopic submucosal dissection (ESD) of esophageal superficial neoplasm is associated with a high en bloc R0 resection rate and low recurrence. OBJECTIVE: We aim to compare the performance and clinical outcomes of ESD via ESD after circumferential incision (ESD-C) versus submucosal tunneling (ESD-T). METHODS: Single-center retrospective analysis of all consecutive patients who underwent ESD for superficial esophageal cancer, between 2009 and 2018. ESD-T was defined as the technique of making the mucosal incisions followed by submucosal tunneling in the oral to anal direction. ESD-C consisted of completing a circumferential incision followed by ESD. Main study outcomes included en bloc and R0 resection rates. Secondary outcomes included procedural characteristics, curative resection rate, local recurrence and adverse events. RESULTS: A total of 65 procedures (23 ESD-T and 42 ESD-C) were performed for ESCC (40; 61.5%) and BE-neoplasia (25; 38.5%). There were no statistically significant differences between patients who underwent ESD-T versus ESD-C in en bloc (91.3% vs 100%, P=0.12), R0 (65.2% vs 78.6%, P=0.24), curative resection rates (65.2% vs 73.8%, P=0.47) and mean procedure time (118.7 min with vs 102.4 min, P=0.35). Adverse events for ESD-T and ESD-C were as follows: bleeding (0 versus 2.4%; P=0.53), perforation (4.3% vs 0; P=0.61), esophageal stricture (8.7% versus 9.5%; P=0.31). Local recurrence was encountered in 8.7% after ESD-T and 2.4% after ESD-C (P=0.28) at a mean follow-up of 8 and 2.75 years, respectively (P=0.001). CONCLUSION: ESD-T and ESD-C appear to be equally effective with similar safety profiles for the management of superficial esophageal neoplasms.


RESUMO CONTEXTO: A dissecção endoscópica submucosa (DES) no tratamento da neoplasia superficial do esôfago está associada a uma alta taxa de ressecção R0 em bloco e baixa taxa de recorrência. OBJETIVO: O objetivo deste estudo é comparar o desempenho e os resultados clínicos da DES com incisão circunferencial (DES-C) versus com DES com túnel submucoso (DES-TS). MÉTODOS: Estudo retrospectivo de banco de dados coletados prospectivamente de um centro especializado em DES, investigando pacientes consecutivos submetidos à DES por câncer de esôfago superficial, entre 2009 e 2018. DES-TS foi definida como a técnica de realizar primeiro incisões na mucosa seguida de tunelamento submucoso no sentido oral para anal. DES-C consistiu em completar uma incisão circunferencial seguida da dissecção submucosa. As principais variáveis do estudo incluíram taxas de ressecção em bloco e R0. Os resultados secundários incluíram características do procedimento, taxa de ressecção curativa, recorrência local e eventos adversos. RESULTADOS: Um total de 65 procedimentos (23 DES-TS e 42 DES-C) foram realizados para CCE de esôfago (40; 61,5%) e neoplasia associada ao EB (25; 38,5%). Não houve diferenças estatisticamente significativas entre os pacientes submetidos a DES-TS versus DES-C nas taxas de ressecção em bloco (91,3% vs 100%, P=0,12), R0 (65,2% vs 78,6%, P=0,24), taxas de ressecção curativa (65,2% vs 73,8%, P=0,47) e tempo médio do procedimento (118,7 min com vs 102,4 min, P=0,35). Os eventos adversos para DES-TS e DES-C foram os seguintes: sangramento (0 vs 2,4%; P=0,53), perfuração (4,3% vs 0; P=0,61), estenose esofágica (8,7% vs 9,5%; P=0,31). A recorrência local foi encontrada em 8,7% após DES-TS e 2,4% após DES-C (P=0,28) em um seguimento médio de 8 e 2,75 anos, respectivamente (P=0,001). CONCLUSÃO: DES-TS e DES-C demostram ser igualmente eficazes com perfil de segurança semelhante para o tratamento das neoplasias superficiais do esôfago.


Assuntos
Humanos , Neoplasias Esofágicas/cirurgia , Estenose Esofágica , Ressecção Endoscópica de Mucosa/efeitos adversos , Estudos Retrospectivos , Resultado do Tratamento , Recidiva Local de Neoplasia
18.
Arch. méd. Camaguey ; 25(1): e7713, tab
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1152926

RESUMO

RESUMEN Fundamento: debido al riesgo de evolución insatisfactoria de los pacientes con esófago de Barrett hacia el adenocarcinoma esofágico, es necesaria la aplicación de técnicas seguras y efectivas que logren prevenir el desenlace hacia lesiones malignas esofágicas. El Hybrid-APC (Argón plasma coagulación) es una de estas técnicas que permiten detener la historia natural del esófago de Barrett en su etapa inicial. Objetivo: realizar una revisión y reflexión acerca del tratamiento endoscópico del esófago de Barrett con el Hybrid-APC. Métodos: se realizó una búsqueda en los motores Google, PudMed, SciELO regional, SciELO Public Health, National Library of Medicine PudMed. En la estrategia de la búsqueda se utilizaron los términos: esófago de Barrett, tratamiento endoscópico, Hybrid-APC. Se evaluaron los documentos en extensos y se desarrolló un documento resumen de la información recolectada. En la búsqueda bibliográfica realizada se encontraron 20 trabajos relacionados con esófago de Barrett, tratamiento endoscópico 10 y específico del uso del Hybrid-APC cinco. Resultados: los estudios reportaron la efectividad y seguridad de la ablación con el Hybrid-APC en el tratamiento endoscópico del esófago de Barrett con displasia de bajo grado; y en la displasia de alto grado y carcinoma in situ remanente, luego de una resección mucosa endoscópica. Conclusiones: el tratamiento endoscópico del esófago de Barrett con Hybrid-APC, se considera una técnica alternativa para detener la evolución de esta enfermedad hacia el adenocarcinoma. Esto generará motivación para entrenamientos y su puesta en práctica de forma generalizada.


ABSTRACT Background: due to the risk of unsatisfactory evolution of patients with Barrett's esophagus (EB) towards esophageal adenocarcinoma, it is necessary to apply safe and effective techniques that prevent the outcome towards esophageal malignant lesions. The Hybrid-APC (argon plasma coagulation) is one of these techniques that allow stopping the natural history of EB in its initial stage. Objective: to conduct a review and reflection on the endoscopic treatment of Barrett's esophagus with the Hybrid-APC. Methods: a search was conducted on Google, PudMed, SciELo regional, SciELo Public Health, National Library of Medicine PudMed engines. The search strategy used the terms: Barrett's esophagus, endoscopic treatment, Hybrid-APC. Extensive documents were evaluated and a summary document of the information collected was developed. The literature search found 20 works related to Barrett's esophagus, ten on endoscopic treatment, and five on specific to the use of Hybrid-APC. Results: studies reported the effectiveness and security of the ablation with the Hybrid-APC in the endoscopic treatment of Barrett's esophagus with low degree dysplasia, and in the high degree dysplasia and remnant carcinoma in situ, after the endoscopic mucous resection. Conclusions: the endoscopic treatment of Barrett's esophagus with Hybrid-APC is considered an alternative technique to stop the evolution of this pathology towards adenocarcinoma. This will generate motivation for training and its implementation in a generalized way.

19.
ARS med. (Santiago, En línea) ; 45(4): 12-19, nov. 11, 2020.
Artigo em Espanhol | LILACS | ID: biblio-1255401

RESUMO

Introducción: el esófago de Barrett es una alteración en la cual la mucosa esofágica se transforma desde un epitelio escamoso a un epitelio columnar con metaplasia intestinal. Endoscópicamente esta lesión se corresponde con la presencia de una mucosa columnar de color rojo salmón por encima de la unión gatroesofágica. Para su diagnóstico se requiere de la sospecha endoscópica y la confirmación histológica. Objetivo: determinar los niveles de coincidencia entre los diagnósticos endoscópicos y las características histopatológicas del esófago de Barrett, a partir del análisis de una serie de casos. Métodos: se realizó un estudio retrospectivo, en el Hospital Clínico Quirúrgico "Joaquín Albarrán" de La Habana, Cuba entre enero de 2017 a junio de 2019, obteniéndose los datos de los registros de biopsias e historias clínicas. Se realizaron cálculos de frecuencias absolutas y relativas y, para evaluar la fuerza de coincidencia entre endoscopia e histología, se utilizó el estadístico Chi cuadrado. Resultados: en los 67 casos con diagnóstico endoscópico la coincidencia con histopatológica fue del 44,8%, en el restante 55,2% de los pacientes las lesiones diagnosticadas fue esofagitis crónica (p = 0,005). Conclusiones: el esófago de Barrett es una de las entidades clínicas con una epidemiología de alta variabilidad y su diagnóstico endos-cópicos requiere de la confirmación histológica ya que existe una baja coincidencia entre el diagnóstico endoscópico e histopatológico del EB el cual es el estándar de oro para el diagnóstico de EB.


Background: Barrett's oesophagus is an alteration in which the oesophagal mucosa is transformed from squamous epithelium to co-lumnar epithelium with intestinal metaplasia. Endoscopically this lesion corresponds to the presence of a salmon-red columnar mucosa above the gastroesophageal junction. For its diagnosis, endoscopic suspicion and histological confirmation are required.Objective: To determine the levels of coincidence between the endoscopic diagnoses and the histopathological characteristics of Barrett's oesophagus, from the analysis of a series of cases. Methods: A retrospective study was carried out at the "Joaquín Albarrán" Surgical Cli-nical Hospital in Havana, Cuba, between January 2017 and June 2019, obtaining data from biopsy records and medical records. Absolute and relative frequency calculations were performed and, to evaluate the force of coincidence between endoscopy and histology, the Chi-square statistic was used. Results: In the 67 cases with endoscopic diagnosis, the coincidence with histopathology was 44.8%, in the remaining 55.2% of the patients the lesions diagnosed were chronic esophagitis (p = 0.005). Conclusions: Barrett's oesophagus is one of the clinical entities with the epidemiology of high variability, and its endoscopic diagnosis requires histological confirmation since there is a low coincidence between the endoscopic and histopathological diagnosis of EB which is the gold standard for EB diagnosis.


Assuntos
Humanos , Esôfago de Barrett , Endoscopia , Histologia , Biópsia , Distribuição de Qui-Quadrado , Registros Médicos , Estudos Retrospectivos , Cuba , Diagnóstico , Mucosa Esofágica , Metaplasia
20.
Rev. colomb. gastroenterol ; 35(3): 311-318, jul.-set. 2020. tab, graf
Artigo em Espanhol | LILACS | ID: biblio-1138788

RESUMO

Resumen Introducción: el esófago de Barrett es un trastorno en el que ocurre un cambio del epitelio escamoso estratificado del esófago por uno columnar especializado, lo cual se da como consecuencia del reflujo gastroesofágico crónico. En Colombia no se conoce la prevalencia actual de esta patología, ni se ha caracterizado a la población que la padece. El presente estudio tiene como objetivo conocer cuáles son las características demográficas principales de la población diagnosticada con esófago de Barrett en dos instituciones médicas de Bogotá. Material y métodos: se realizó un estudio de corte transversal multicéntrico, en el cual se evaluaron los reportes de endoscopias y de histopatología de 3000 pacientes que asistieron a estas instituciones por cualquier indicación. A partir de estos reportes se tomaron los datos requeridos. Asimismo, se realizó un análisis estadístico descriptivo de dichos datos. Resultados: la prevalencia del esófago de Barrett en la muestra es del 0,73 %. Se observó, además, que la correlación endoscópico-patológica es baja (28,5 %). De los casos diagnosticados, el rango de edad más frecuente se ubica entre los 60 y 80 años, con una edad promedio de 65,5 años. Asimismo, existe una predominancia de esta patología en el sexo femenino (63,6 %), en personas con un índice de masa corporal (IMC) >25 kg/m² y en aquellas con antecedentes de tabaquismo, sin historial de consumo de alcohol. En la mayoría de pacientes, se realizó la endoscopia por síntomas de reflujo gastroesofágico (50 %). La longitud del segmento observado no fue reportada en una gran cantidad de endoscopias. Conclusiones: en las instituciones analizadas, el esófago de Barrett es una patología de muy baja prevalencia y predominante en mujeres de edad avanzada con síntomas de reflujo gastroesofágico, sobrepeso y antecedente de tabaquismo.


Abstract Introduction: Barrett's esophagus occurs when the stratified squamous epithelium of the esophagus changes to a specialized columnar epithelium as a result of chronic gastroesophageal reflux. Its current prevalence in Colombia is unknown and the population suffering from it has not been characterized. The present study aims to determine the main demographic characteristics of the population diagnosed with Barrett's esophagus treated at two medical centers in Bogotá, Colombia. Materials and methods: A multicenter cross-sectional study was conducted to assess the endoscopy and histopathology reports of 3,000 patients who underwent this procedure for any reason. A descriptive statistical analysis of the data was performed. Results: The prevalence of Barrett's esophagus in the sample was 0.73%. The endoscopic-histology correlation was low (28.5%). Of the diagnosed cases, the most frequent age range was 60-80 years, with an average age of 65.5 years. This condition is predominant in the female sex (63.6%), in people with a BMI over 25 kg/m², with a history of smoking, and no history of alcohol consumption. Most patients underwent endoscopy for symptoms associated with gastroesophageal reflux (50%). The length of the observed segment was not reported in most endoscopies. Conclusions: In the medical centers included in this study, Barrett's esophagus is a rare pathology, found predominantly in elderly women with symptoms of gastroesophageal reflux, overweight, and with a history of smoking.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , População , Esôfago de Barrett , Estudos Transversais , Sexo , História
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...